Sermorelin (Research-Grade Peptide)

Investigational GHRH analog (Growth Hormone-Releasing Hormone) — for laboratory research only

Product Overview

Sermorelin, also known as sermorelin acetate or GHRH(1-29), is a synthetic peptide analog consisting of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). This peptide is designed to bind to GHRH receptors on the anterior pituitary gland, stimulating the pulsatile release of endogenous growth hormone (GH). Unlike direct growth hormone replacement, sermorelin activates the body’s natural growth hormone secretion pathway, preserving physiological feedback regulation and circadian rhythms. Supplied as high-purity lyophilized powder, this material is intended strictly for research use and not for human or veterinary administration.

Research Highlights

• GHRH Receptor Mechanism: Sermorelin activates growth hormone-releasing hormone receptors on the anterior pituitary, stimulating endogenous GH secretion in a pulsatile pattern that mirrors natural physiological release, supporting bone remodeling, lean mass, and metabolic function in research models.
  Wiley JCSM (2020),
  Wikipedia Clinical Overview
• Lean Mass and Body Composition: A 1997 randomized placebo-controlled trial in elderly adults (ages 60-78) demonstrated that sermorelin treatment for 16 weeks increased IGF-1 levels to approach those of younger men (ages 22-33), with male subjects gaining an average of 1.26 kg of lean body mass and notable improvements in skin thickness and subjective well-being.
  Journal of Clinical Endocrinology & Metabolism,
  Peptides Research Summary
• Age-Related Growth Hormone Decline: Research indicates that growth hormone secretion declines approximately 14% per decade after age 30, correlating with increases in visceral adiposity, reduced bone mineral density, and diminished insulin sensitivity. Sermorelin research explores mechanisms to restore GH-IGF-1 axis function.
  Journal of Clinical Endocrinology & Metabolism (Age-Related Decline)
• Bone Mineral Density: Growth hormone stimulates bone-forming cells through IGF-1 signaling. Research in growth hormone secretagogue development demonstrates mechanisms for supporting bone mineral density and skeletal remodeling, with studies in postmenopausal women showing lumbar spine bone density improvements with GH-stimulating therapies.
  NIH Clinical Trials Database,
  Anti-Aging Research Summary

Product Details & Handling

• Synonyms: Sermorelin; Sermorelin acetate; GHRH(1-29); Geref (brand name); GRF(1-29)
• Form: Lyophilized powder, supplied in sterile vials
• Purity: ≥ 98% (Certificate of Analysis provided)
• Storage: Store at –20 °C; protect from light and moisture
• Handling: Use only in controlled laboratory settings with appropriate PPE; consult SDS for detailed safety information

Legal Disclaimer

This product is provided strictly for laboratory research use only.
It is not intended for human or veterinary consumption, therapeutic, diagnostic, or clinical application.
Customers are responsible for compliance with all applicable laws and institutional policies.
Sermorelin is an investigational compound not approved by the FDA as a new drug for adult wellness (though it was previously FDA-approved for pediatric growth hormone deficiency diagnosis).
This product is not a supplement, treatment, or medication. Windy City Peptide does not provide medical advice or support related to human use.